Literature DB >> 18053428

Targets, trials, and travails in pancreas cancer.

Kamel Izeradjene1, Sunil R Hingorani.   

Abstract

Pancreas cancer is a highly aggressive and rapidly fatal disease. The current standard of care for advanced disease improves survival modestly at best and provides palliation for a minority of patients. The need for new therapies is undisputed. This article describes new therapeutic strategies currently under investigation and discusses possible reasons that others have failed. New potential targets in the treatment of this formidable disease are suggested based on recent findings.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18053428     DOI: 10.6004/jnccn.2007.0087

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  6 in total

1.  Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.

Authors:  William W Tseng; Daniel Winer; Justin A Kenkel; Okmi Choi; Alan H Shain; Jonathan R Pollack; Randy French; Andrew M Lowy; Edgar G Engleman
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

2.  Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.

Authors:  Navid Farr; Yak-Nam Wang; Samantha D'Andrea; Frank Starr; Ari Partanen; Kayla M Gravelle; Jeannine S McCune; Linda J Risler; Stella G Whang; Amy Chang; Sunil R Hingorani; Donghoon Lee; Joo Ha Hwang
Journal:  Int J Hyperthermia       Date:  2017-07-17       Impact factor: 3.914

Review 3.  ERBBs in the gastrointestinal tract: recent progress and new perspectives.

Authors:  William H Fiske; David Threadgill; Robert J Coffey
Journal:  Exp Cell Res       Date:  2008-11-07       Impact factor: 3.905

4.  Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope.

Authors:  Ben M Chue
Journal:  Gastrointest Cancer Res       Date:  2009-09

5.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

6.  A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies.

Authors:  Kaustav Majumder; Nivedita Arora; Shrey Modi; Rohit Chugh; Alice Nomura; Bhuwan Giri; Rajinder Dawra; Sundaram Ramakrishnan; Sulagna Banerjee; Ashok Saluja; Vikas Dudeja
Journal:  J Gastrointest Surg       Date:  2015-11-18       Impact factor: 3.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.